Tevogen Bio announced top-line revenue forecasts for its specialty care pipeline, projecting $1 billion in revenue in the launch year and $10-$14 billion over the first five years. The company specializes in developing off-the-shelf T cell therapeutics for infectious diseases and cancers. Tevogen aims to address unmet patient needs with its innovative drug development model. The company’s leadership believes in sustainable medical innovation through advanced science and disruptive business models.

One of Tevogen Bio’s key developments is the treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2 infection. The company’s forecast for its Oncology therapeutic area includes treatments for various cancers, such as B cell hematologic cancer and EBV-associated lymphomas. Tevogen’s clinical-stage specialty immunotherapy biotech aims to provide accessible personalized therapeutics to large patient populations. The company’s positive safety data from proof-of-concept trials shows promise in its mission to innovate healthcare.

Read more at – Tevogen Bio forecasts $1 billion in launch year for Oncology therapeutic area. (GlobeNewswire): REPEAT — Tevogen Bio Specialty Care Reports Top-Line